ESR1 and breast cancer: Notably, both estrogen receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer subtypes showed similar sensitivity, indicating a mechanism independent of hormone receptor status—particularly valuable given the limited treatment options for triple-negative breast cancer.